Paxil CR™
Partner: GlaxoSmithKline
Enhancing the therapeutic profile of Paxil™ for GSK
Paxil CR™ is an improved oral formulation of GlaxoSmithKline's Paxil™ (paroxetine), a leading selective serotonin reuptake inhibitor antidepressant. Paxil CR™, taken once a day, uses SkyePharma's Geomatrix™ technology to reduce gastrointestinal side-effects, a major cause of non-compliance, especially in new patients.
The use of Geomatrix™ in Paxil CR™ moves the location of absorption to the lower intestine, thereby reducing the incidence of nausea. In clinical trials this resulted in a significant reduction in the drop-out rate due to adverse events and an improved efficacy.
Paxil CR™ was launched in the USA in April 2002.
For further information on Paxil CR™, see GlaxoSmithKline's website.
Copyright 2008, SkyePharma. All Rights Reserved.
SkyePharma PLC is a public limited company registered in England and Wales, registration number 0107582.
Registered office: 105 Piccadilly, London, W1J 7NJ, United Kingdom
